# Novo Nordisk CEO Comments on Ozempic Pricing ## Key Points: – Novo Nordisk CEO, Lars Fruergaard Jorgensen, attributes the high price of Ozempic to pharmacy benefit managers (PBMs) and insurance companies. – Jorgensen states that despite the company’s efforts to keep the price of Ozempic reasonable, the involvement of PBMs and insurers escalates the final cost for patients. – The CEO emphasizes the need for a better system that directly benefits patients, as current intermediaries are impacting drug prices significantly. ## Hot Take: Novo Nordisk’s CEO sheds light on the challenges faced by pharmaceutical companies when it comes to pricing their medications. Despite their intentions to provide affordable options like Ozempic, the influence of PBMs and insurers can hinder accessibility for patients. This insight highlights the importance of advocating for a more transparent and patient-centric approach within the healthcare system. *Weight loss disclaimer: Individual results may vary. Please contact Mindful Evolution for a personalized weight loss plan. We offer telehealth services in Alabama, Arkansas, Florida, Georgia, Louisiana, Mississippi, North Carolina, New York, South Carolina, Tennessee, Texas, and Virginia.* Contact Mindful Evolution at https://yourmindfulevolution.com or call or text us at 954-639-9960.